IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Considering its susceptibility to immune system attack and the favorable results obtained with IFN-α in the pre-TKI era [38], CML qualifies as an ideal scenario for combination therapies with TKIs and IFN-α.